(Q34122535)

31 July 2017

1 reference

title

Cefdinir: an expanded-spectrum oral cephalosporin (English)

1 reference

31 July 2017

1 reference

D R Guay

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 December 2000

1 reference

Annals of Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

34

1 reference

31 July 2017

issue

12

1 reference

31 July 2017

page(s)

1469-1477

1 reference

FK 482, a new orally active cephalosporin synthesis and biological properties

31 July 2017

cites work

1 reference

The effects of quinolones on the adherence of type-1 fimbriated Escherichia coli to mannosylated agarose beads.

21 January 2018

1 reference

The in-vitro activity of cefdinir (FK482), a new oral cephalosporin

21 January 2018

1 reference

In vitro activity of cefdinir (FK 482, PD 134393, CI-983): a new orally active cephalosporin.

21 January 2018

1 reference

Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines.

21 January 2018

1 reference

In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin.

21 January 2018

1 reference

In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients.

21 January 2018

1 reference

Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin

21 January 2018

1 reference

Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, gram-negative bacilli and respiratory tract pathogens

21 January 2018

1 reference

In vitro evaluation of cefdinir (FK482), a new oral cephalosporin with enhanced antistaphylococcal activity and beta-lactamase stability.

21 January 2018

1 reference

In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production.

21 January 2018

1 reference

Susceptibility testing interpretive criteria and drug stability for cefdinir, cefetamet, and cefpodoxime against Neisseria gonorrhoeae.

21 January 2018

1 reference

Antimicrobial activity of three investigational oral cephalosporins (BK-218, cefdinir, and RU29246) against Legionella

21 January 2018

1 reference

Antistaphylococcal activity of cefdinir, a new oral third-generation cephalosporin, alone and in combination with other antibiotics, at supra- and sub-MIC levels.

21 January 2018

1 reference

Stability of cefdinir (C1-983, FK482) to extended-spectrum plasmid-mediated beta-lactamases.

21 January 2018

1 reference

Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases

21 January 2018

1 reference

Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices.

21 January 2018

1 reference

Suction-induced blister fluid penetration of cefdinir in healthy volunteers following ascending oral doses

21 January 2018

1 reference

A study of 5-day cefdinir treatment for streptococcal pharyngitis in children. Cefdinir Pediatric Pharyngitis Study Group

21 January 2018

1 reference

Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group.

21 January 2018

1 reference

Efficacy and safety of cefdinir in the treatment of patients with acute bronchitis. The Cefdinir Bronchitis Study Group.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.19407

1 reference

31 July 2017

1 reference